Special Issue

Recent Progress of Nanomedicine and Targeted Drug Delivery for Cancer Treatment 2.0

Message from the Guest Editors

Cancer is the second leading cause of death worldwide and is the most complex and challenging disease known to mankind. Effective cancer treatment is still a great challenge due to the complex underlying mechanisms of tumorigenesis and tumor metastasis, as well as the intrinsic limitations of conventional cancer therapies. There is an urgent need for the discovery of novel therapeutic strategies with superior anticancer capabilities. In recent years, nano-drug delivery systems have been extensively investigated and applied as alternatives to conventional cancer treatments. Cancer nanomedicines aim at the targeted delivery of chemotherapeutic drugs to the tumor site, and utilize strategies such as passive targeting, active targeting, and stimuli-triggered drug release, while simultaneously decreasing drug accumulation in normal tissues; together, they lead to improved therapeutic efficacy and reduced side effects.

This Special Issue will highlight recent progress in the development of novel nanomedicines and targeted drug delivery systems for cancer therapy. All original Articles or comprehensive Reviews will be welcomed.

Guest Editors

Dr. Huijie Zhang

School of Life Sciences and Health Engineering, Jiangnan University, Wuxi, China

Dr. Shini Feng

School of Life Sciences, Shanghai University, Shanghai, China

Deadline for manuscript submissions

closed (25 August 2024)



Pharmaceuticals

an Open Access Journal by MDPI

Impact Factor 4.8 CiteScore 7.7 Indexed in PubMed



mdpi.com/si/166929

Pharmaceuticals
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
pharmaceuticals@mdpi.com

mdpi.com/journal/ pharmaceuticals





Pharmaceuticals

an Open Access Journal by MDPI

Impact Factor 4.8 CiteScore 7.7 Indexed in PubMed



About the Journal

Message from the Editor-in-Chief

Because of your expertise in the field of drug sciences, I kindly invite you to consider publishing your current work, in the form of a research article or a review, in the open access electronic journal *Pharmaceuticals*. *Pharmaceuticals* is characterized by an active editorial board and a dynamic editorial staff. Manuscripts are peer-reviewed and a final decision is provided to authors within 4–6 weeks after submission. Papers are published on the web immediately after acceptance. For details on the submission process or any other matter, please do not hesitate to contact us.

We hope to handle your contribution to *Pharmaceuticals* soon.

Editor-in-Chief

Prof. Dr. Amélia Pilar Rauter

Departamento de Química e Bioquímica (DQB) e Centro de Química Estrutural (CQE), Institute of Molecular Sciences, Faculdade de Cièncias, Universidade de Lisboa, Lisboa, Portugal

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Pharmaceutical Science)

